{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T02:50:53Z","timestamp":1788922253629,"version":"build-2803163510"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Dainippon Sumitomo Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012412","name":"Kansai Medical University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012412","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Neurology"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.expneurol.2025.115383","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:01:53Z","timestamp":1752678113000},"page":"115383","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Zonisamide modulates cholinergic markers and alleviates levodopa-induced dyskinesia in a rat model of Parkinson's disease"],"prefix":"10.1016","volume":"393","author":[{"given":"Satoshi","family":"Morise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rie","family":"Tohge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuaki","family":"Oki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihiro","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirofumi","family":"Kusaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Yakushiji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.expneurol.2025.115383_bb0005","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","article-title":"Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice","volume":"6","author":"Anagnostaras","year":"2003","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.expneurol.2025.115383_bb0010","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S0306-4522(03)00220-3","article-title":"Co-expression of alpha7 and beta2 nicotinic acetylcholine receptor subunit mRNAs within rat brain cholinergic neurons","volume":"119","author":"Azam","year":"2003","journal-title":"Neuroscience"},{"key":"10.1016\/j.expneurol.2025.115383_bb0015","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/wnf.0b013e3180413d7d","article-title":"Clinical pharmacology and mechanism of action of zonisamide","volume":"30","author":"Biton","year":"2007","journal-title":"Clin. Neuropharmacol."},{"key":"10.1016\/j.expneurol.2025.115383_bb0020","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.nbd.2016.02.019","article-title":"Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias","volume":"91","author":"Bordia","year":"2016","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2025.115383_bb0025","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/S0197-4580(02)00065-9","article-title":"Staging of brain pathology related to sporadic Parkinson\u2019s disease","volume":"24","author":"Braak","year":"2003","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.expneurol.2025.115383_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105044","article-title":"Striatal and nigral muscarinic type 1 and type 4 receptors modulate levodopa-induced dyskinesia and striato-nigral pathway activation in 6-hydroxydopamine hemilesioned rats","volume":"144","author":"Brugnoli","year":"2020","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2025.115383_bb0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.neuropharm.2016.07.025","article-title":"Monoamine transporter contributions to l-DOPA effects in hemi-parkinsonian rats","volume":"110","author":"Conti","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2025.115383_bb0040","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.neubiorev.2018.05.021","article-title":"A new outlook on cholinergic interneurons in Parkinson\u2019s disease and L-DOPA-induced dyskinesia","volume":"92","author":"Conti","year":"2018","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.expneurol.2025.115383_bb0045","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1073\/pnas.1006511108","article-title":"Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice","volume":"108","author":"Ding","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.expneurol.2025.115383_bb0050","article-title":"Levetiracetam ameliorates L-DOPA-induced dyskinesia in Hemiparkinsonian rats inducing critical molecular changes in the striatum","volume":"2015","author":"Du","year":"2015","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2025.115383_bb0055","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1002\/ana.25364","article-title":"Levodopa-induced dyskinesia in Parkinson disease: current and evolving concepts","volume":"84","author":"Espay","year":"2018","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.expneurol.2025.115383_bb0060","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.bbr.2006.07.004","article-title":"Sexually dimorphic postural adjustments during vertical behaviour are altered in a unilateral 6-OHDA rat model of Parkinson\u2019s disease","volume":"174","author":"Field","year":"2006","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.expneurol.2025.115383_bb0065","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/sj.npp.1301461","article-title":"Selective effects of cholinergic modulation on task performance during selective attention","volume":"33","author":"Furey","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.expneurol.2025.115383_bb0070","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1126\/science.289.5479.633","article-title":"Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function","volume":"289","author":"Kaneko","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.expneurol.2025.115383_bb0075","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/mds.100","article-title":"Diverse serotonin actions of vilazodone reduce l-3,4-dihidroxyphenylalanine-induced dyskinesia in hemi-parkinsonian rats","volume":"33","author":"Meadows","year":"2018","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2025.115383_bb0080","first-page":"17","article-title":"Effects of carbamazepine and zonisamide on acetylcholine levels in rat striatum","volume":"17","author":"Mizuno","year":"1997","journal-title":"Nihon Shinkei Seishin Yakurigaku Zasshi"},{"key":"10.1016\/j.expneurol.2025.115383_bb0085","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.bcp.2016.03.023","article-title":"Brain \u03b17 nicotinic acetylcholine receptors in MPTP-lesioned monkeys and parkinsonian patients","volume":"109","author":"Morissette","year":"2016","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.expneurol.2025.115383_bb0090","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/mds.26286","article-title":"Zonisamide improves wearing-off in Parkinson\u2019s disease: a randomized, double-blind study","volume":"30","author":"Murata","year":"2015","journal-title":"Mov. Disord."},{"key":"10.1016\/j.expneurol.2025.115383_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.expneurol.2025.115383_bb0100","first-page":"8626783","article-title":"Zonisamide enhances motor effects of levodopa, not of apomorphine, in a rat model of Parkinson\u2019s disease","volume":"2018","author":"Nishijima","year":"2018","journal-title":"Parkinsons Dis."},{"key":"10.1016\/j.expneurol.2025.115383_bb0105","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0920-1211(95)00078-X","article-title":"Effects of zonisamide on dopaminergic system","volume":"22","author":"Okada","year":"1995","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.expneurol.2025.115383_bb0110","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.neures.2017.04.003","article-title":"Zonisamide ameliorates levodopa-induced dyskinesia and reduces expression of striatal genes in Parkinson model rats","volume":"122","author":"Oki","year":"2017","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.expneurol.2025.115383_bib161","series-title":"The Rat Brain in stereotaxic Coordinates","author":"Paxinos","year":"2007"},{"key":"10.1016\/j.expneurol.2025.115383_bb0115","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1007\/s00702-018-1845-9","article-title":"The striatal cholinergic system in L-dopa-induced dyskinesias","volume":"125","author":"Perez","year":"2018","journal-title":"J. Neural Transm. (Vienna)"},{"key":"10.1016\/j.expneurol.2025.115383_bb0120","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tins.2007.07.008","article-title":"Re-emergence of striatal cholinergic interneurons in movement disorders","volume":"30","author":"Pisani","year":"2007","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.expneurol.2025.115383_bb0125","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fncir.2017.00110","article-title":"Dopamine and acetylcholine, a circuit point of view in Parkinson\u2019s disease","volume":"11","author":"Rizzi","year":"2017","journal-title":"Front. Neural Circ."},{"key":"10.1016\/j.expneurol.2025.115383_bb0130","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.neuint.2019.01.011","article-title":"The effects of zonisamide on L-DOPA-induced dyskinesia in Parkinson\u2019s disease model mice","volume":"124","author":"Sano","year":"2019","journal-title":"Neurochem. Int."},{"key":"10.1016\/j.expneurol.2025.115383_bb0135","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1111\/j.1742-4658.2008.06296.x","article-title":"Parkinson\u2019s disease: levodopa-induced dyskinesia and signal transduction","volume":"275","author":"Santini","year":"2008","journal-title":"FEBS J."},{"key":"10.1016\/j.expneurol.2025.115383_bb0140","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.expneurol.2016.03.024","article-title":"Enkephalin and dynorphin neuropeptides are differently correlated with locomotor hypersensitivity and levodopa-induced dyskinesia in parkinsonian rats","volume":"280","author":"Sgroi","year":"2016","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.expneurol.2025.115383_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2021.108771","article-title":"Zonisamide attenuates the severity of levodopa-induced dyskinesia via modulation of the striatal serotonergic system in a rat model of Parkinson's disease","volume":"198","author":"Tohge","year":"2021","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.expneurol.2025.115383_bb0150","first-page":"105","article-title":"Maladaptive synaptic plasticity in L-DOPA-induced dyskinesia","volume":"10","author":"Wang","year":"2016","journal-title":"Front. Neural Circ."},{"key":"10.1016\/j.expneurol.2025.115383_bb0155","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1006\/nbdi.2002.0499","article-title":"L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson\u2019s disease: relation to motor and cellular parameters of nigrostriatal function","volume":"10","author":"Winkler","year":"2002","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.expneurol.2025.115383_bb0160","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1523\/JNEUROSCI.2888-13.2014","article-title":"Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice","volume":"34","author":"Won","year":"2014","journal-title":"J. Neurosci."}],"container-title":["Experimental Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448862500247X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001448862500247X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T04:29:00Z","timestamp":1779769740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001448862500247X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":33,"alternative-id":["S001448862500247X"],"URL":"https:\/\/doi.org\/10.1016\/j.expneurol.2025.115383","relation":{},"ISSN":["0014-4886"],"issn-type":[{"value":"0014-4886","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Zonisamide modulates cholinergic markers and alleviates levodopa-induced dyskinesia in a rat model of Parkinson's disease","name":"articletitle","label":"Article Title"},{"value":"Experimental Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.expneurol.2025.115383","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115383"}}